Alexion submits application to Japan ’s MHLW to extend Soliris indication to treat gMG

Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news